Corey Lab

Corey Lab

Corey lab group photo

Our Research


Welcome to the Corey Lab. Our lab focuses on the pathogenesis of chronic viral infections and host immune responses. This includes herpes simplex virus type 2 (HSV-2) and HIV. We use HSV as a model to study the tissue based immune system of the genital tract. Our studies indicate a diverse and unique set of tissue resident cells populate the genital tract and our work is devoted to identifying and understanding the role of these cells in disease pathogenesis. The ultimate goal for these projects is to develop immunotherapeutic methods to control subclinical HSV-2 reactivation and reduce the transmission to sexual partners. Our lab has also initiated several preclinical studies to use adoptive transfer of genetically engineered T cells to traffic to and be effectors in lymphoid follicles with a goal to eradicate HIV infections.

 

Publications

The Journal of Virology 2019

Acute Infection and Subsequent Subclinical Reactivation of Herpes Simplex Virus 2 after Vaginal Inoculation of Rhesus Macaques. Lo M, Zhu J, Hansen SG, Carroll T, Farr Zuend C, Nöel-Romas L, Ma ZM, Fritts L, Huang ML, Sun S, Huang Y, Koelle DM, Picker LJ, Burgener A, Corey L, Miller CJ.

The Journal of Experimental Medicine 2017

Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation. Peng T, Chanthaphavong RS, Sun S, Trigilio JA, Phasouk K, Jin L, Layton ED, Li AZ, Correnti CE, De van der Schueren W, Vazquez J, O'Day DR, Glass IA, Knipe DM, Wald A, Corey L, Zhu J. 

Recent News

Despite early rise, longterm ART decreases HSV shedding

Science Spotlight | B Traxinger | Dec. 17, 2018

HVTN'S LARGE-SCALE HIV VACCINE EFFICACY TRIALS FULLY ENROLLED

JUNE 21, 2019
The HIV Vaccine Trials Network (HVTN), headquartered at the Fred Hutchinson Cancer Research Center, has fully enrolled its four ongoing large-scale HIV vaccine efficacy trials. 

New HIV vaccine trial to launch in U.S., Latin America and Europe

Hutch News | Sabin Russell | July 17, 2019
‘Mosaico’ will enroll 3,800 transgender people and men who have sex with men